Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: A meta-analysis

European Journal of Cancer Care

Volumn 22, Issue 1, 2013, Pages 41-50

  Jin, Chen ^a   Sun, W ^b   Gu, D ^b   Yang, J ^b   Xu, Z ^b   Chen, J ^b  

^a THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy induced nausea and vomiting; Meta analysis; Palonosetron; The 5 HT3 receptor antagonists

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ISOQUINOLINE DERIVATIVE; PALONOSETRON; QUINUCLIDINE DERIVATIVE; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST;

ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; HUMAN; META ANALYSIS; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; ISOQUINOLINES; NAUSEA; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; SEROTONIN ANTAGONISTS; VOMITING;

EID: 84871717511     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2012.01353.x     Document Type: Article

References (31)

1. Aapro M.S., Grunberg S.M., Manikhas G.M., Olivares G., Suarez T., Tjulandin S.A., Bertoli L.F., Yunus F., Morrica B., Lordick F. & Macciocchi A. (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Annals of Oncology 17, 1441-1449.
2. Bernardo G., Palumbo R., Frascaroli M., Bernardo A., Losurdo A., Poggi G., Teragni C., Albanese D., Amatu A. & Strada M.R. (2009) Palonosetron compared to ondansetron in the prevention of chemotherapy-induced nausea and vomiting: activity, safety, and cost-effectiveness evaluation. Journal of Clinical Oncology 27, e20573.
3. Constenla M. (2004) 5-HT3 receptor antagonists for prevention of late acute-onset emesis. Annals of Pharmacotherapy 38, 1683-1691.
4. DerSimonian R. & Laird N. (1986) Meta-analysis in clinical trials. Controlled Clinical Trials 7, 177-188.
5. Dong X., Huang J., Cao R. & Liu L. (2011) Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. Medical Oncology 28, 1425-1529.
6. Eisenberg P., Figueroa-Vadillo J., Zamora R., Charu V., Hajdenberg J., Cartmell A., Macciocchi A. & Grunberg S. (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98, 2473-2482.
7. Eisenberg P., Mackintosh F.R., Ritch P., Cornett P.A. & Macciocchi A. (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Annals of Oncology 15, 330-337.
8. Gao H., Liang Y., Zhou N., Zhang D. & Wu H. (2011) Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin-based chemotherapy. Internal Medicine Journal (Epub ahead of print).
9. Gonullu G., Demircan S., Demirag M.K., Erdem D. & Yucel I. (2011) Electrocardiographic findings of palonosetron in cancer patients. Supportive Care in Cancer (Epub ahead of print).
10. Gralla R., Lichinitser M., Van Der Vegt S., Sleeboom H., Mezger J., Peschel C., Tonini G., Labianca R., Macciocchi A. & Aapro M. (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Annals of Oncology 14, 1570-1577.
11. Grunberg S.M., Deuson R.R., Mavros P., Geling O., Hansen M., Cruciani G., Daniele B., De Pouvourville G., Rubenstein E.B. & Daugaard G. (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100, 2261-2268.
12. Hamadani M., Awab A., Chaudhary L. & Tfayli A. (2006) Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy. Journal of Oncology Pharmacy Practice 12, 67-68.
13. Ho K.Y. & Gan T.J. (2006) Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Current Opinion in Anaesthesiology 19, 606-611.
14. Jordan K., Hinke A., Grothey A., Voigt W., Arnold D., Wolf H.H. & Schmoll H.J. (2007) A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Supportive Care in Cancer 15, 1023-1033.
15. Kaushal J., Gupta M.C., Kaushal V., Bhutani G., Dhankar R., Atri R. & Verma S. (2010) Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Singapore Medical Journal 51, 871-875.
16. Likun Z., Xiang J., Yi B., Xin D. & Tao Z.L. (2011) A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. The Oncologist 16, 207-216.
17. Maemondo M., Masuda N., Sekine I., Kubota K., Segawa Y., Shibuya M., Imamura F., Katakami N., Hida T. & Takeo S. (2009) A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Annals of Oncology 20, 1860-1866.
18. Mattiuzzi G.N., Cortes J.E., Blamble D.A., Bekele B.N., Xiao L., Cabanillas M., Borthakur G., O'brien S. & Kantarjian H. (2010) Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 116, 5659-5666.
19. Musso M., Scalone R., Bonanno V., Crescimanno A., Polizzi V., Porretto F., Bianchini C. & Perrone T. (2009) Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Supportive Care in Cancer 17, 205-209.
20. Navari R.M. (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting - two new agents. Journal of Supportive Oncology 1, 89-103.
21. Navari R.M., Einhorn L.H., Passik S.D., Loehrer P.J., Sr, Johnson C., Mayer M.L., Mcclean J., Vinson J. & Pletcher W. (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Supportive Care in Cancer 13, 529-534.
22. Osoba D., Zee B., Warr D., Latreille J., Kaizer L. & Pater J. (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Supportive Care in Cancer 5, 307-313.
23. Rojas C., Thomas A.G., Alt J., Stathis M., Zhang J., Rubenstein E.B., Sebastiani S., Cantoreggi S. & Slusher B.S. (2010)Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. European Journal of Pharmacology 626, 193-199.
24. Saito M., Aogi K., Sekine I., Yoshizawa H., Yanagita Y., Sakai H., Inoue K., Kitagawa C., Ogura T. & Mitsuhashi S. (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncology 10, 115-124.
25. Schwartzberg L., Morrow G., Balu S., Craver C., Gayle J. & Cox D. (2011) Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT(3)receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States. Current Medical Research and Opinion 27, 1613-1622.
26. Sepulveda-Vildosola A.C., Betanzos-Cabrera Y., Lastiri G.G., Rivera-Marquez H., Villasis-Keever M.A., Del Angel V.W., Diaz F.C. & Lopez-Aguilar E. (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Archives of Medical Research 39, 601-606.
27. Stoltz R., Cyong J.C., Shah A. & Parisi S. (2004) Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. Journal of Clinical Pharmacology 44, 520-531.
28. Tian W., Wang Z., Zhou J., Zhang S., Wang J., Chen Q., Huang C., Pan L., Zhang L., Huang J., Shen H. & Lin T. (2011) Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population. Medical Oncology 28, 71-78.
29. Watcha M.F. (2002) Postoperative nausea and emesis. Anesthesiology Clinics of North America 20, 709-722.
30. Wender R.H. (2009) Do current antiemetic practices result in positive patient outcomes? Results of a new study. American Journal of Health-System Pharmacy 66, S3-S10.
31. Yu Z., Liu W., Wang L., Liang H., Huang Y., Si X., Zhang H. & Liu D. (2009) The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Supportive Care in Cancer 17, 99-102.